Revolution Medicines’ (RVMD) Buy Rating Reiterated at HC Wainwright

Revolution Medicines (NASDAQ:RVMD – Get Free Report)‘s stock had its “buy” rating reiterated by HC Wainwright in a report issued on Tuesday, Benzinga reports. They currently have a $350.00 price target on the stock. HC Wainwright‘s price target suggests a potential upside of 109.74% from the stock’s current price.

Other research analysts have also recently issued reports about the company. Stifel Nicolaus upped their price target on Revolution Medicines from $215.00 to $230.00 and gave the stock a “buy” rating in a research note on Wednesday, September 9th. TD Cowen raised their price target on Revolution Medicines from $250.00 to $270.00 and gave the stock a “buy” rating in a research report on Thursday, November 5th. Brookline Capital Markets started coverage on Revolution Medicines in a research note on Monday, September 28th. They issued a “buy” rating and a $318.00 price objective for the company. Oppenheimer boosted their price objective on Revolution Medicines from $230.00 to $260.00 and gave the company an “outperform” rating in a report on Thursday, August 27th. Finally, Morgan Stanley decreased their target price on Revolution Medicines from $272.00 to $247.00 and set an “overweight” rating on the stock in a research note on Friday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $262.75.

Get Our Latest Stock Report on RVMD

Revolution Medicines Price Performance

Revolution Medicines stock opened at $166.87 on Tuesday. The company’s 50 day simple moving average is $193.60 and its 200-day simple moving average is $159.77. The company has a market capitalization of $36.09 billion, a price-to-earnings ratio of -18.32 and a beta of 1.44. Revolution Medicines has a 1 year low of $67.27 and a 1 year high of $224.31. The company has a debt-to-equity ratio of 0.44, a quick ratio of 8.34 and a current ratio of 8.36.

Revolution Medicines (NASDAQ:RVMD – Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The company reported ($1.90) EPS for the quarter, topping the consensus estimate of ($2.35) by $0.45. The company had revenue of $197.56 million during the quarter, compared to analyst estimates of $25.58 million. During the same quarter in the prior year, the company posted ($1.61) earnings per share. As a group, equities research analysts expect that Revolution Medicines will post -7.41 earnings per share for the current year.

Insider Activity

In other Revolution Medicines news, COO Margaret A. Horn sold 4,967 shares of the firm’s stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $199.24, for a total value of $989,625.08. Following the completion of the transaction, the chief operating officer owned 149,680 shares of the company’s stock, valued at $29,822,243.20. This trade represents a 3.21% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Jack Anders sold 35,750 shares of the business’s stock in a transaction on Wednesday, November 11th. The stock was sold at an average price of $188.10, for a total transaction of $6,724,575.00. Following the completion of the transaction, the chief financial officer owned 119,216 shares of the company’s stock, valued at approximately $22,424,529.60. This trade represents a 23.07% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 326,741 shares of company stock worth $66,147,340 over the last 90 days. Company insiders own 7.60% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Equitable Holdings Inc. acquired a new position in Revolution Medicines during the 2nd quarter worth $963,000. State of Wyoming acquired a new position in shares of Revolution Medicines during the second quarter worth about $1,769,000. Handelsbanken Fonder AB grew its position in shares of Revolution Medicines by 243.6% during the second quarter. Handelsbanken Fonder AB now owns 212,275 shares of the company’s stock worth $39,755,000 after buying an additional 150,500 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Revolution Medicines during the second quarter worth approximately $112,566,000. Finally, Assenagon Asset Management S.A. purchased a new stake in shares of Revolution Medicines during the second quarter worth approximately $37,547,000. 94.34% of the stock is currently owned by hedge funds and other institutional investors.

Revolution Medicines Company Profile

(Get Free Report)

Revolution Medicines, Inc. is a biotechnology company focused on developing targeted therapies for patients with RAS-driven cancers. Founded in 2014 and headquartered in Redwood City, California, the company’s research centers on RAS proteins, which can contribute to the growth of many cancers. The company’s pipeline includes drug candidates designed to inhibit mutant RAS proteins, including daraxonrasib (RMC-6236), which targets multiple RAS variants, and candidates directed at specific KRAS mutations.

Featured Articles

Analyst Recommendations for Revolution Medicines (NASDAQ:RVMD)

Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.